Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials

Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials

Sustained weight loss improves liver histology in non‐alcoholic fatty liver disease. This post hoc analysis of four phase III, 56‐week, randomized controlled trials investigated if extended‐release naltrexone and bupropion (NB) affects alanine aminotransferase (ALT) and Fibrosis‐4 (FIB‐4) index in a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes, obesity & metabolism obesity & metabolism, 2021-03, Vol.23 (3), p.861-865
Hauptverfasser: Bajaj, Harpreet S., Burrows, Melonie, Blavignac, Jessica, Paron, Emilia, Camacho, Fernando, Gould, Errol, Barakat, Maxime
Format: Artikel
Sprache:eng
Schlagworte:
Alanine
Alanine transaminase
antiobesity drug, clinical trial, fatty liver disease, obesity therapy, phase III study, randomized trial
Body mass index
Body weight
Body weight loss
Bupropion
Clinical trials
Fatty liver
Fibrosis
Liver
Liver diseases
Naltrexone
Obesity
Overweight
Placebos
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sustained weight loss improves liver histology in non‐alcoholic fatty liver disease. This post hoc analysis of four phase III, 56‐week, randomized controlled trials investigated if extended‐release naltrexone and bupropion (NB) affects alanine aminotransferase (ALT) and Fibrosis‐4 (FIB‐4) index in adults with overweight or obesity. Two thousand and seventy‐three subjects (NB = 1310; placebo = 763; 79.0% female; 81.6% Caucasian) had baseline mean weight 101 kg, body mass index 36.2 kg/m2, ALT 26.9 IU/L and FIB‐4 0.79. At 56 weeks, NB‐treated subjects experienced more weight loss than placebo (8.7 vs. 3.2 kg, respectively, P
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14284